

Kidney Week 2026

Please join us for an **Exhibitor Spotlight**, featuring an expert panel discussion

Why Aldosterone Matters for Kidney Outcomes in CKM Syndrome

Friday, October 23, 2026 • Colorado Convention Center, Denver, Colorado
Exhibit Hall A, Theater 1 • 10:15 AM – 11:00 AM

This program will examine the role of RAAS dysregulation and aldosterone in cardiovascular-kidney-metabolic (CKM) syndrome and review the impact of excess aldosterone on cardiovascular and kidney disease progression. The speakers will discuss the bidirectional relationship between kidney and cardiovascular disease, the clinical consequences of aldosterone dysregulation, and current guideline-based approaches for managing patients with chronic kidney disease (CKD) and heart failure (HF). Through review of the evidence and discussion of their clinical experience, speakers will explore the ongoing burden of aldosterone-related risk and the potential for therapeutic strategies to slow kidney disease progression and improve cardiovascular outcomes.

EXPERT PANEL



**Robert Page II, PharmD, MSPH, BCPS (AQ-cards),
FAHA, FHFA, FCCP, FASHP**

Professor of Clinical Pharmacy, Medicine, and Physical Medicine
Clinical Specialist, Division of Cardiology
CU Skaggs School of Pharmacy and Pharmaceutical Sciences
CU School of Medicine
University of Colorado Anschutz Medical Campus
Aurora, Colorado



Janani Rangaswami, MD, FACP, FAHA

Professor of Medicine
George Washington University School of Medicine
Washington, DC

Supported by Boehringer Ingelheim Pharmaceuticals, Inc.
The Exhibitor Spotlight is not a continuing education (CE) activity.

Copyright © 2026 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. SC-US-84100 August 2026

